Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Ohio State University Wexner Medical Center

Sites in Columbus, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1591
Shown on this page
12
Current sort
Recently updated
Campus scope
Ohio State University Wexner Medical Center, Columbus, OH
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Ohio State University Wexner Medical Center, Columbus, OH. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 589–600 of 1,591 matching trials with a site at Ohio State University Wexner Medical Center, Columbus, OH.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

NCT02003222
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Leucovorin Calcium, Lumbar Puncture, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
30 Years to 70 Years
Enrollment
488 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
531
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Recruiting Not applicable Interventional

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

NCT04592445
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF
Interventions
Greater Splanchnic Nerve Ablation, Sham Control
Device
Lead sponsor
Axon Therapies, Inc.
Industry
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Recruiting Phase 1 Interventional

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

NCT06529822
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer
Interventions
Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera or Altera testing
Biological · Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
3
States / cities
Orlando, Florida • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial

NCT07567040
Status at this site: Recruiting
View directory record Official record
Conditions
Myopia
Interventions
Atropine Sulfate 0.05% Oph Soln, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
6 Years to 11 Years
Enrollment
664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Berkeley, California • Fullerton, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Active, not recruiting Phase 2 Interventional

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

NCT06773910
Site status not listed — check the official record
View directory record Official record
Conditions
Limited Stage Small Cell Lung Cancer
Interventions
BMS-986489, Durvalumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
34
States / cities
Daphne, Alabama • Santa Barbara, California • Fort Myers, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Not yet recruiting Not applicable Interventional

Nutrition Supplement for Cystic Fibrosis

NCT07163078
Site status not listed — check the official record
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
Common form supplementation, Uncommon nutrient supplementation
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Recruiting Phase 2 Interventional

Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking

NCT07214207
Status at this site: Recruiting
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Suvorexant 10 mg, Placebo
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634
Site status not listed — check the official record
View directory record Official record
Conditions
Myositis
Interventions
Nipocalimab, Placebo, Glucocorticoids
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

NCT06732401
Site status not listed — check the official record
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Echocardiography Test
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
192
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Los Angeles, California + 163 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Not yet recruiting Not applicable Interventional

The Hear Clear Study

NCT07824115
Site status not listed — check the official record
View directory record Official record
Conditions
Hearing Loss
Interventions
Signal-to-Noise Ratio Enhancement (SNR+), Signal-to-Noise Ratio Neutral (SNR-)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Durham, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Recruiting Phase 3 Interventional

Study of ALK-001 on the Progression of Stargardt Disease

NCT07419334
Status at this site: Recruiting
View directory record Official record
Conditions
Stargardt Disease
Interventions
ALK-001, Placebo
Drug
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 45 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
14
States / cities
Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Recruiting Phase 2Phase 3 Interventional

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796
Status at this site: Recruiting
View directory record Official record
Conditions
Neoplasms
Interventions
Gene-modified (GM) T cell therapy
Genetic
Lead sponsor
Celgene
Industry
Eligibility
Not listed
Enrollment
1,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2043
U.S. locations
103
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 31, 2026, 4:36 AM EDT

About this Ohio State University Wexner Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Ohio State University Wexner Medical Center in Columbus, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.